Physician
Impact Healthcare, PLLC
Impact Healthcare, PLLC was paid $10.11M by Medicaid between Jan 2018 and Dec 2024, across 33 billing codes. Its largest line is H0016, Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) — 65% of everything it billed.
33Billing provider infoIMPACT HEALTHCARE, PLLC
JACKSON, TN 38305
JACKSON, TN 38305
33aNPI1487185153assigned 03/24/2017
33bProvider typeAddiction Medicine (Family Medicine) Physician
28Total paid$10.11M
24GClaims163,298
24DCodes billed33
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Addiction Medicine (Family Medicine) Physician providers in Tennessee
Rank by total paid#1 of 16
Median peer was paid$151K
This provider vs. median67×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,567 | $129K | |
| 2019 | 12,047 | $452K | |
| 2020 | 14,201 | $946K | |
| 2021 | 46,447 | $3.42M | |
| 2022 | 42,652 | $2.29M | |
| 2023 | 26,800 | $1.78M | |
| 2024incomplete | 14,584 | $1.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 65% | 34,014 | 23,728 | $6.60M |
| H0033 | Oral medication administration, direct observation | 7.7% | 5,229 | 4,065 | $776K |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 7.3% | 2,053 | 1,499 | $742K |
| 99484 | 4.7% | 19,553 | 16,467 | $471K | |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | 4.3% | 1,922 | 895 | $434K |
| 80305 | 2.3% | 47,887 | 30,621 | $234K | |
| H0049 | Alcohol and/or drug screening | 1.9% | 11,381 | 6,626 | $187K |
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | 1.6% | 5,552 | 4,092 | $158K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.5% | 10,557 | 6,369 | $154K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.3% | 3,131 | 2,406 | $128K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 2,029 | 872 | $92K |
| 81025 | <1% | 9,931 | 7,171 | $34K |
21 more codes
| G2086 | Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month | <1% | 163 | $31K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 648 | $14K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,847 | $12K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,187 | $9K |
| 99205 | Prolong outpt/office vis | <1% | 133 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 171 | $7K |
| 99492 | <1% | 76 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 560 | $5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 77 | $3K |
| 99406 | <1% | 705 | $2K | |
| 99401 | <1% | 182 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 618 | $820.12 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 498 | $591.98 |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 496 | $364.37 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 80 | $146.38 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 15 | $97.32 |
| 80074 | <1% | 18 | $59.17 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 46 | $43.12 |
| 4004F | <1% | 875 | $0.04 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 404 | $0.02 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 260 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTURNER, ANDREW (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Pathway Healthcare- Mississippi LLC | Vicksburg, MS | $2.61M |
| Impact Behavioral Counseling LLC | Dallas, TX | $255K |
| Impact Healthcare, PLLC | Springfield, TN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.